Gastrointestinal Cancer

Ivosidenib induced a 63% reduction in the risk of disease progression or death versus placebo in previously treated patients with IDH1-mutant advanced cholangiocarcinoma, according to findings from the phase 3 ClarIDHy study published in the Lancet Oncology.

Ivosidenib induced a 63% reduction in the risk of disease progression or death versus placebo in previously treated patients with IDH1-mutant advanced cholangiocarcinoma, according to findings from the phase 3 ClarIDHy study published in the Lancet Oncology.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Neehar Parikh, MD, sheds light on the role of multidisciplinary care in hepatocellular carcinoma, other therapeutic modalities on the horizon, and anticipated sequencing challenges in the paradigm.

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Neehar Parikh, MD, sheds light on the role of multidisciplinary care in HCC, other therapeutic modalities on the horizon, and anticipated sequencing challenges in the paradigm. 

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Shai Friedland, MD, discusses the importance of screening for colorectal cancer, the advantages of the noninvasive FirstSightCRC blood test, and the results from the ZENITH trial.

Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.

Riad Salem, MD, discusses the role of localized therapy in hepatocellular carcinoma, the need to personalize treatment for patients, and the importance of implementing a multidisciplinary approach in this setting.

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

A supplemental New Drug Application has been submitted to the Japanese Ministry of Health, Labour and Welfare seeking approval of trastuzumab deruxtecan for the treatment of patients with HER2-positive metastatic gastric cancer

Hagen F. Kennecke, MD, discusses treatment selection, peptide receptor radionuclide therapy, and remaining challenges in the field of gastroenteropancreatic neuroendocrine tumors.

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Diane M. Simeone, MD, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.

The FDA has granted an orphan drug designation to MIV-818 for the treatment of patients with hepatocellular carcinoma.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Aman Chauhan, MD, discusses recent developments and emerging therapies in gastroenteropancreatic neuroendocrine tumors.

Manuel Hidalgo Medina, MD, PhD, discusses some of the research he presented at the 2020 ACCR Virtual Annual Meeting and future areas of exciting efforts being made in pancreatic cancer.

FGFR2 fusions are significantly less common in endemic fluke-associated cholangiocarcinoma compared with non–fluke-associated cholangiocarcinoma, demonstrating that distinct etiologies could affect the molecular landscape of cholangiocarcinoma tumors.

The combination of nivolumab and regorafenib demonstrated promising antitumor activity in patients with gastric and colorectal cancer.

During an OncLive® scientific interchange, panelists discussed the current treatment landscape for patients with gastroenteropancreatic-neuroendocrine tumors and the need for improved novel therapies.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.